Research programme: quinolone antibacterials - Procter & GambleAlternative Names: (3S)-Amino-(4R)-ethylpiperidinyl quinolones research programme - Procter & Gamble; 5,6-Bridged dioxinoquinolones research programme - Procter & Gamble; Non-fluorinated quinolones research programme - Procter & Gamble; PGE 836779; Quinolone antibacterials research programme - Procter & Gamble
Latest Information Update: 01 Dec 2009
At a glance
- Originator Procter & Gamble
- Class Quinolones
- Mechanism of Action DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 06 Jan 2005 TaiGen Biotechnology entered a strategic alliance with Procter & Gamble for further development and commercialisation of an unspecified, non-fluorinated quinolone invented by Procter & Gamble. TaiGen has development and commercialisation rights in China, Taiwan, Korea and the ASEAN countries
- 07 Jan 2004 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
- 05 Sep 2003 This programme is still in active development